Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALIANT-AF-T: Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation
NCT06953726Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jun 2026
- Primary completion
- Oct 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apixaban, rivaroxaban in Atrial fibrillation (AFib), atrial flutter (AFL), sponsored by VA Office of Research & Development. Started Jun 2026; status: recruiting.
02
Drugs
apixabanrivaroxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT06953726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953726.